Breaking News

Aptar Pharma, i2c Pharma Services Partner on Next-Gen pMDI

Aptar has exclusive option for a worldwide license to i2c’s Respitab technology.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Aptar Pharma, a global provider of drug delivery systems, services and active material science solutions, and i2c Pharmaceutical Services, a service provider for the development of pharmaceutical formulations, entered an exclusive partnership to co-develop and promote i2c’s pressurized metered dose inhaler (pMDI) technology, Respitab.   As part of the agreement, Aptar Pharma, a market leader in pulmonary drug delivery device solutions for COPD, will evaluate the commercial applications for Res...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters